CT83 and cancer: KK-LC-1 is also a CTA that is reported to be highly expressed in gastric cancer, breast cancer, lung cancer, and is currently being explored for safety and tolerability in clinical trials against KK-LC-1 highly-expressing tumors in clinical trials for many cancers (Table 1).